Executive Summary
On February 23, 2026, 15 NASDAQ-100 related companies filed 8-Ks, dominated by neutral sentiment (14/15) and a cluster of material definitive agreements (Item 1.01 in MoonLake Immunotherapeutics, Gilead Sciences, International Battery Metals Ltd., Keurig Dr Pepper Inc.), signaling potential M&A or strategic partnership wave across biotech, battery, and consumer sectors. High materiality standouts include Gilead (9/10), MoonLake/Keurig/Intl Battery (8/10 each), far exceeding portfolio average of 4.8/10, indicating outsized developments. No quantitative period-over-period comparisons, financial ratios, operational metrics, or guidance disclosed across any filing, limiting trend synthesis on revenue growth or margins. Common themes: equity dilution risks (Item 3.02 in 2 companies), officer changes (Item 5.02 in Entravision, Mueller Water), governance shifts (AI Tech Solutions), and results disclosures (ImmunityBio, Apple Hospitality REIT) without details. Portfolio implications: Biotech/pharma shows elevated activity (4/15 filings); monitor for follow-on details on undisclosed deals amid medium risk levels; no insider activity or capital allocation signals detected.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from February 19, 2026.
Investment Signals(11)
- MoonLake Immunotherapeutics↓(BULLISH)▲
Multi-item 8-K with material definitive agreement (Item 1.01), financial obligation (Item 2.03), results (Item 2.02), Reg FD (Item 7.01); materiality 8/10 vs avg 4.8/10
- Gilead Sciences↓(BULLISH)▲
Entry into material definitive agreement (Item 1.01) + Reg FD disclosure (Item 7.01); highest materiality 9/10, outlier vs peers
- Keurig Dr Pepper Inc.↓(BULLISH)▲
Multi-item incl material agreement (Item 1.01), Reg FD (Item 7.01), large 2MB filing size signaling substance; materiality 8/10
- International Battery Metals Ltd.↓(BULLISH)▲
Material definitive agreement (Item 1.01) despite equity sales; materiality 8/10 in battery sector
- ImmunityBio, Inc.↓(BULLISH)▲
Results of operations (Item 2.02) disclosure in biotech cluster; low risk, potential positive update
- Apple Hospitality REIT (2nd filing)(NEUTRAL-BULLISH)▲
Earnings-related results (Item 2.02), materiality 6/10 vs REIT peer 3/10
- Entravision Communications Corp↓(NEUTRAL-BULLISH)▲
Officer election/appointment (Item 5.02), potential leadership refresh; materiality 6/10
- Inmune Bio, Inc.↓(NEUTRAL-BULLISH)▲
Other events (Item 8.01) in biotech group, consistent with sector momentum
Reg FD disclosure (Item 7.01) amid AI theme, despite governance items; materiality 6/10
- Mueller Water Products, Inc.↓(NEUTRAL)▲
Officer change (Item 5.02), potential positive compensatory arrangements
- Verizon Communications Inc↓(NEUTRAL)▲
Other events (Item 8.01), telecom stability signal
Risk Flags(9)
- MoonLake Immunotherapeutics/Disclosure Gap↓[MEDIUM RISK]▼
No details on material agreement, financial obligation, or results; medium risk, uncertainty on impacts
- Gilead Sciences/Agreement Opacity↓[MEDIUM RISK]▼
Material definitive agreement undisclosed terms/values; highest materiality amplifies uncertainty
- International Battery Metals Ltd./Dilution↓[HIGH RISK]▼
Unregistered equity sales (Item 3.02) + mixed sentiment; potential shareholder dilution
- Keurig Dr Pepper Inc./Dilution↓[HIGH RISK]▼
Unregistered equity sales (Item 3.02) alongside material agreement; dilution vs deal benefits unclear
Material mods to security holder rights (Item 3.03) + bylaws/fiscal changes (Item 5.03); rights erosion risk
- Entravision Communications Corp/Officer Change↓[MEDIUM RISK]▼
Departure of directors/officers (Item 5.02) without reasons/names; continuity concerns
- Mueller Water Products, Inc./Leadership↓[MEDIUM RISK]▼
Undisclosed officer departure/appointment details (Item 5.02); operational disruption potential
- ImmunityBio, Inc./Earnings Opacity↓[LOW-MEDIUM RISK]▼
Results filing (Item 2.02) lacks metrics/guidance; low materiality but assessment limited
- OptimumBank Holdings, Inc./Event Unknown↓[LOW-MEDIUM RISK]▼
Item 8.01 other events undisclosed; potential hidden risks
Opportunities(8)
- Gilead Sciences/M&A Catalyst↓(OPPORTUNITY)◆
Material agreement (Item 1.01) in pharma leader, 9/10 materiality outlier; alpha from deal synergies/accretions
- MoonLake Immunotherapeutics/Strategic Deal↓(OPPORTUNITY)◆
Multi-developments incl agreement + Reg FD; biotech partnership potential at 8/10 materiality
- Keurig Dr Pepper/Consumer M&A↓(OPPORTUNITY)◆
Material agreement + Reg FD in large-cap consumer; 2MB filing hints at scale, monitor terms
- International Battery Metals/Battery Growth↓(OPPORTUNITY)◆
Material agreement offsets dilution; EV/battery sector tailwind
- Biotech Cluster (MoonLake, Gilead, ImmunityBio, Inmune Bio)(OPPORTUNITY)◆
4/15 filings same day; sector momentum for relative outperformance
- Entravision Communications/Leadership Refresh↓(OPPORTUNITY)◆
New officer arrangements (Item 5.02); media recovery play if positive hire
- Apple Hospitality REIT/Earnings↓(OPPORTUNITY)◆
Dual filings incl results (Item 2.02); REIT yield opportunity if occupancy implied stable
- AI Tech Solutions/Reg FD(OPPORTUNITY)◆
Disclosure (Item 7.01) in AI name; governance changes could unlock value
Sector Themes(6)
- M&A/Agreement Surge(THEME)◆
4/15 companies (27%) filed Item 1.01 (MoonLake, Gilead, Intl Battery, Keurig) on same day; elevated deal flow vs historical norms, bullish for growth but watch valuations
- Biotech/Pharma Concentration(THEME)◆
4/15 filings (MoonLake, Gilead, ImmunityBio, Inmune Bio) with results/agreements/events; cluster suggests sector catalysts, outpacing other groups
- Equity Dilution Pattern(THEME)◆
2/15 (13%) with Item 3.02 unregistered sales (Intl Battery, Keurig); funding for deals but EPS pressure, bearish short-term
- Leadership Turnover Wave(THEME)◆
3/15 companies (Entravision, Mueller, implied in others) via Item 5.02; transition risks but opportunity for stronger teams
- Governance/Structure Shifts(THEME)◆
Items 3.03/5.03 in AI Tech Solutions + bylaws elsewhere; 2+ instances signal changes, monitor for shareholder value impacts
- Neutral Disclosure Dominance(THEME)◆
14/15 neutral sentiment, no guidance/insider data; low conviction environment, favors patient investors on high-materiality names
Watch List(8)
Follow for deal terms, financial obligation details post-2/23/2026; high 8/10 materiality
Reg FD + Item 1.01 details expected soon; 9/10 materiality outlier, potential guidance
Unregistered sales vs material deal balance; large filing warrants Q&A updates
Equity sales impact + agreement fit; mixed sentiment, track share overhang
Security rights mods (Item 3.03); watch proxy/earnings for rationale
Departure/appointment follow-up; assess interim leadership stability
Item 2.02 metrics release expected; biotech cluster context amplifies
Results (Item 2.02) + events; REIT dividend implications post-2/23/2026
Filing Analyses(15)
23-02-2026
MoonLake Immunotherapeutics filed a Form 8-K on February 23, 2026 (AccNo: 0001213900-26-018967), reporting multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing indicating several material corporate developments, but specific transaction details, financial metrics, dollar values, and impacts are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, or named entities beyond the filer are provided.
23-02-2026
Entravision Communications Corp filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-061961), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, names, reasons for change, timing, or any quantitative metrics are disclosed.
23-02-2026
Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 23, 2026, reporting under Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific details on the modifications, amendments, disclosures, or exhibits are provided, resulting in no quantifiable positive or negative metrics. This multi-item filing appears informational without disclosed financial or operational impacts.
23-02-2026
Gilead Sciences, Inc. filed an 8-K on 2026-02-23 reporting under Item 1.01 entry into a material definitive agreement, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No details on the nature of the agreement, transaction value, financial impacts, or other quantitative metrics are disclosed. This is a multi-item mandatory filing for Items 1.01 and 9.01 with Item 7.01 often accompanying forward-looking disclosures.
- ·AccNo: 0001104659-26-018314
23-02-2026
ImmunityBio, Inc. filed an 8-K on February 23, 2026 (AccNo: 0001326110-26-000025), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, period-over-period comparisons, revenue, earnings, guidance, or other quantitative data are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed results provided.
23-02-2026
OptimumBank Holdings, Inc. filed a Form 8-K on February 23, 2026, reporting under Item 8.01 Other Events, which covers material events not specified elsewhere, and Item 9.01 Financial Statements and Exhibits, indicating attachments are included. No specific details on the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the filing summary. This appears to be a multi-item informational filing with no quantified positive or negative impacts provided.
- ·AccNo: 0001493152-26-007689
- ·File Size: 229 KB
23-02-2026
Trilogy Metals Inc. filed an 8-K on February 23, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No specific events, transactions, financial metrics, or quantitative data are disclosed in the filing summary. This appears to be a voluntary disclosure with attached exhibits.
23-02-2026
Inmune Bio, Inc. filed a Form 8-K on February 23, 2026 (AccNo: 0001213900-26-019321, size: 226 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events or the content of the financial statements and exhibits are disclosed. This is a multi-item informational filing with no quantified financial or operational metrics provided.
23-02-2026
Apple Hospitality REIT, Inc. filed an 8-K on February 23, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial metrics, or exhibits are disclosed in the provided filing information.
23-02-2026
Apple Hospitality REIT, Inc. filed a Form 8-K on 2026-02-23 disclosing Results of Operations and Financial Condition under Item 2.02, with Financial Statements and Exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be an informational earnings-related disclosure without detailed performance data.
23-02-2026
International Battery Metals Ltd. filed a Form 8-K on February 23, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 3.02 unregistered sales of equity securities, accompanied by exhibits under Item 9.01. This multi-item mandatory filing highlights significant corporate actions, where the material agreement represents a potentially strategic development while the unregistered equity sales introduce potential shareholder dilution. No specific transaction values, financial impacts, or other quantitative details are provided.
23-02-2026
Mueller Water Products, Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are provided in the available information. No quantitative metrics, financial impacts, or performance comparisons are mentioned.
23-02-2026
Verizon Communications Inc filed an 8-K on February 23, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are disclosed in the filing summary provided.
23-02-2026
Keurig Dr Pepper Inc. filed a Form 8-K on 2026-02-23 (AccNo: 0001193125-26-064353, Size: 2 MB) reporting multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item mandatory disclosure with no specific transaction details, financial metrics, dollar values, or period-over-period comparisons provided in the summary. No positive or negative quantitative impacts are disclosed.
- ·Filing Accession Number: 0001193125-26-064353
- ·Filing Size: 2 MB
Get daily alerts with 11 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 15 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC